CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 142 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
Mr. Arthur Kuan es el Chairman of the Board de CG Oncology Inc, se unió a la empresa desde 2017.
¿Qué tal es el rendimiento del precio de la acción CGON?
El precio actual de CGON es de $69.51, ha disminuido un 0.03% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de CG Oncology Inc?
CG Oncology Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de CG Oncology Inc?
La capitalización bursátil actual de CG Oncology Inc es $5.8B
¿Es CG Oncology Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 16 analistas han realizado calificaciones de análisis para CG Oncology Inc, incluyendo 3 fuerte compra, 13 compra, 1 mantener, 0 venta, y 3 fuerte venta
